IKT
Inhibikase Therapeutics, Inc. Common Stock
stockNASDAQ
inhibikase therapeutics, inc., a clinical stage pharmaceutical company, develops therapeutics for parkinson's disease, and related disorders that arise inside and outside of the brain. the company's product candidates include ikt-148009, a c-abl protein kinase inhibitor for use in the treatment of parkinson's disease, dysphagia, and neurogenic constipation; and ikt-001pro, a prodrug of the anti-cancer agent imatinib that is in preclinical development to minimize gastrointestinal side effects. it offers products comprise ikt-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body; and ikt-148x series of portfolio compounds for use in the treatment of dementia with lewy body and multiple system atrophy. the company was founded in 2008 and is headquartered in atlanta, georgia.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 2.05 | 2026-09-28 | -2.19% | 3.076 |
| 1M | 2.50 | 2026-09-04 | -19.80% | 0.444 |
| 3M | 1.98 | 2026-07-06 | +1.26% | 0.950 |
| 6M | 1.79 | 2026-04-06 | +12.01% | 1.109 |
| 1Y | 1.62 | 2025-10-06 | +23.77% | 1.372 |
| 2Y | 1.26 | 2024-10-04 | +59.13% | — |
| 5Y | 11.16 | 2021-10-05 | -82.03% | 0.928 |
Inhibikase Therapeutics, Inc. Common Stock (NASDAQ:IKT) stock price today is $2.01, and today's volume is 170,550. IKT is up 0.250% today. The 30 day average volume is 514,522. IKT market cap is $279.77M with 139.54M shares outstanding.